Last reviewed · How we verify
Fluzone High-Dose vaccine, 2018-2019 formulation
Fluzone High-Dose vaccine, 2018-2019 formulation, is a marketed product by Sanofi Pasteur, a leading player in the influenza vaccine market. A key strength is the protection it offers for the elderly population, a segment highly susceptible to severe flu complications. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic manufacturers.
At a glance
| Generic name | Fluzone High-Dose vaccine, 2018-2019 formulation |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults (PHASE2)
- Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: